Vaxxinity Inc (VAXX) USD0.0001 A
$0.0001
(25.00%)
- Add to watchlist
- This stock can be held in a
$0.0001
(25.00%)
Deal for just £11.95 per trade in a
Fund and Share Account
$0.0001
(25.00%)
Business summary
Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the potential to enable a new class of medicines. Its pipeline consists of five lead programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Its pipeline includes UB-311, UB-312, VXX-301, VXX-401 and UB-313. It also has developed an infectious disease product candidate, UB-612, as a heterologous booster against COVID-19. Its UB-311, which targets the primary pathological process of Alzheimer’s disease (AD) and UB-312, which targets the pathological process of Parkinson’s disease (PD) and other so-called synucleinopathies.
Contact details
Important dates
General stock information
- Short code:
- VAXX
- ISIN:
- US92244V1044
- Market cap:
- $63,390
- Shares in issue:
- 126.78 million
- Sector:
- Biotechnology
- Exchange:
- Off Exchange
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.